Evaluation of COX-2, EGFR, and p53 as biomarkers of non-dysplastic oral leukoplakias

Exp Mol Pathol. 2010 Oct;89(2):197-203. doi: 10.1016/j.yexmp.2010.06.004. Epub 2010 Jul 1.

Abstract

Objective: Identify candidate SEBs (surrogate endpoint biomarkers) for premalignant trends in head and neck mucosa.

Study design: Study, by qPCR (quantitative real-time polymerase chain reaction), the expression of COX-2, EGFR and p53 in 24 biopsies of non-dysplastic oral leukoplakia and contra-lateral normal-appearing mucosa.

Results: COX-2 was up-regulated in leukoplakia (79.2%); whereas EGFR and p53 were up-regulated (p>0.05) in oral contra-lateral normal-appearing mucosa (60% and 46% respectively). Also, p53 expression was correlated with tobacco smoke habits and Spearman's rank correlation coefficient showed a positive linear correlation between p53 and EGFR mRNA expression levels.

Conclusions: COX-2 would serve as SEB of oral leukoplakia. The results suggest that p53 appears to be one of the molecular targets of tobacco-related carcinogens in leukoplakia and that the co-expression of p53 and EGFR may play a role in this kind of oral pre-cancerous lesion. More detailed studies of EGFR and p53 should be continued in the future.

Publication types

  • Evaluation Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Biomarkers / metabolism
  • Biopsy
  • Case-Control Studies
  • Cyclooxygenase 2 / metabolism*
  • ErbB Receptors / metabolism*
  • Female
  • Humans
  • Leukoplakia, Oral / genetics
  • Leukoplakia, Oral / metabolism*
  • Leukoplakia, Oral / pathology*
  • Male
  • Middle Aged
  • Mouth Mucosa / chemistry
  • Mouth Mucosa / metabolism
  • Mouth Mucosa / pathology
  • Tumor Suppressor Protein p53 / analysis*
  • Tumor Suppressor Protein p53 / genetics
  • Tumor Suppressor Protein p53 / metabolism*

Substances

  • Biomarkers
  • Tumor Suppressor Protein p53
  • Cyclooxygenase 2
  • PTGS2 protein, human
  • ErbB Receptors